Solventum, formerly 3M Health Care, announced today the launch of the 3M™ Harvest RC Centrate Chromatographic Clarifier, a ...

CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.

The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

Dr. Meg Richards from Panalgo discusses how real-world data is unlocking advancements in drug safety during pregnancy.

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), proudly announces the launch of its new mission statement and tagline: Empowering Partners. Enriching Lives. This ...